Compare · MRK vs NATR
MRK vs NATR
Side-by-side comparison of Merck & Company Inc. (MRK) and Nature's Sunshine Products Inc. (NATR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and NATR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $359.22B, about 1615.1x NATR ($222.4M).
- Over the past year, MRK is up 66.2% and NATR is down 12.9% - MRK leads by 79.1 points.
- MRK has hit the wire 16 times in the past 4 weeks while NATR has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 5 for NATR).
- Company
- Merck & Company Inc.
- Nature's Sunshine Products Inc.
- Price
- $142.20-2.24%
- $12.80+0.71%
- Market cap
- $359.22B
- $222.4M
- 1M return
- -1.75%
- -5.04%
- 1Y return
- +66.15%
- -12.93%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 5
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Nature's Sunshine Products Inc.
Nature's Sunshine Products, Inc., a natural health and wellness company, primarily manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. It also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. The company offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is based in Lehi, Utah.
Latest MRK
- SEC Form 8-K filed by Merck & Company Inc.
- Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
- Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
- Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
- CAPVAXIVE® Included in Ontario's Publicly Funded Adult Pneumococcal Immunization Program
Latest NATR
- EVP, Chief Financial Officer Perkins Ruth Ann was granted 75,433 shares (SEC Form 4)
- SEC Form 3 filed by new insider Perkins Ruth Ann
- SVP, Chief Accounting Officer Lanoy Jonathan David was granted 7,210 shares, increasing direct ownership by 15% to 55,602 units (SEC Form 4)
- Large owner Prescott Group Capital Management, L.L.C. bought $293,800 worth of shares (20,000 units at $14.69) (SEC Form 4)
- Large owner Prescott Group Capital Management, L.L.C. bought $2,318,912 worth of shares (141,389 units at $16.40) (SEC Form 4)
- SEC Form 10-Q filed by Nature's Sunshine Products Inc.
- Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- Nature's Sunshine Reports Second Quarter 2026 Results
- Nature's Sunshine Appoints Ruth Perkins as Executive Vice President and Chief Financial Officer
- Nature’s Sunshine Appoints Janine Weber as Executive Vice President and President, North America